SCYX
Scynexis
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
SCYX Profile
Scynexis, Inc.
A biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections
1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302-6548
--
Scynexis, Inc., was originally incorporated in Delaware on November 4, 1999. Scynexis, Inc., is pioneering innovative medicines that have the potential to help millions of patients around the world who need new options to overcome and prevent difficult-to-treat and drug-resistant infections. Scynexis is developing the lead product candidate ibrexafungerp as a broad-spectrum intravenous (IV)/oral agent for a variety of fungal indications in community and hospital settings. In June 2021 and December 2022, Scynexis announced FDA approval of BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection, and to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively. In October 2022, Scynexis announced that it is actively seeking a US commercialization partner to license out BREXAFEMME in order to refocus resources on the clinical development of ibrexafungerp for serious hospital indications, while keeping BREXAFEMME on the market and available to patients, while Scynexis has stopped actively promoting BREXAFEMME.